A few days before announcing plans to sell itself to Wright Medical Group, BioMimetic Therapeutics signed new employment agreements with two of its top officers and moved to limit the excise taxes CEO Sam Lynch might have to pay.

BioMimetic last week agreed with CFO Larry Bullock (left in our photo) and Vice President of Clinical and Regulatory Affairs Russ Pagano on new contracts. The details are available here, but it's worth noting that Bullock's new deal runs only through next summer — the one-year contract was made retroactive to this July — while Pagano's is scheduled to run through mid-2014. Wright officials said Monday they intend to close on their purchase of Franklin-based BioMimetic in early 2013. In addition, they plan to retain the company's roughly 50 employees and continue its research work outside of the promising Augment bone graft treatment.